These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34351647)

  • 1. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
    Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
    Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation characteristics and clinical significance of
    Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R
    Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716
    [No Abstract]   [Full Text] [Related]  

  • 4. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
    Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
    Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
    Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
    J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Chen Y; Zheng J; Weng Y; Wu Z; Luo X; Qiu Y; Lin Y; Hu J; Wu Y
    Ann Hematol; 2024 Apr; 103(4):1211-1220. PubMed ID: 38409598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Loke J; Labopin M; Craddock C; Cornelissen JJ; Labussière-Wallet H; Wagner-Drouet EM; Van Gorkom G; Schaap NPM; Kröger NM; Veelken JH; Rovira M; Menard AL; Bug G; Bazarbachi A; Giebel S; Brissot E; Nagler A; Esteve J; Mohty M
    Cancer; 2022 Aug; 128(15):2922-2931. PubMed ID: 35612815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and characteristics of patients with
    Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM
    Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
    Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
    [No Abstract]   [Full Text] [Related]  

  • 11. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 in MDS and AML: Biological and clinical advances.
    Zhao Y; Chen W; Yu J; Pei S; Zhang Q; Shi J; Huang H; Zhao Y
    Cancer Lett; 2024 Apr; 588():216767. PubMed ID: 38417666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.
    Bahaj W; Kewan T; Gurnari C; Durmaz A; Ponvilawan B; Pandit I; Kubota Y; Ogbue OD; Zawit M; Madanat Y; Bat T; Balasubramanian SK; Awada H; Ahmed R; Mori M; Meggendorfer M; Haferlach T; Visconte V; Maciejewski JP
    J Hematol Oncol; 2023 Aug; 16(1):91. PubMed ID: 37537667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of subclonal
    Prochazka KT; Pregartner G; Rücker FG; Heitzer E; Pabst G; Wölfler A; Zebisch A; Berghold A; Döhner K; Sill H
    Haematologica; 2019 Mar; 104(3):516-523. PubMed ID: 30309854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with
    Patel SA; Cerny J; Gerber WK; Ramanathan M; Ediriwickrema A; Tanenbaum B; Hutchinson L; Meng X; Flahive J; Barton B; Gillis-Smith AJ; Suzuki S; Khedr S; Selove W; Higgins AW; Miron PM; Simin K; Woda B; Gerber JM
    EJHaem; 2023 Nov; 4(4):1059-1070. PubMed ID: 38024632
    [No Abstract]   [Full Text] [Related]  

  • 16. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
    Kaur A; Rojek AE; Symes E; Nawas MT; Patel AA; Patel JL; Sojitra P; Aqil B; Sukhanova M; McNerney ME; Wu LP; Akmatbekov A; Segal J; Tjota MY; Gurbuxani S; Cheng JX; Yeon SY; Ravisankar HV; Fitzpatrick C; Lager A; Drazer MW; Saygin C; Wanjari P; Katsonis P; Lichtarge O; Churpek JE; Ghosh SB; Patel AB; Menon MP; Arber DA; Wang P; Venkataraman G
    Blood Cancer J; 2024 Jun; 14(1):99. PubMed ID: 38890297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
    Novak ER; Deshpande A; Finlay D; Mason JR; Deshpande AJ; Adams PD; Li S
    Methods Mol Biol; 2023; 2594():87-95. PubMed ID: 36264490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
    Bataller A; Kantarjian H; Bazinet A; Kadia T; Daver N; DiNardo CD; Borthakur G; Loghavi S; Patel K; Tang G; Sasaki K; Short NJ; Yilmaz M; Issa GC; Alvarado Y; Montalban-Bravo G; Maiti A; Abbas HA; Takahashi K; Pierce S; Jabbour E; Garcia-Manero G; Ravandi F
    Haematologica; 2024 May; ():. PubMed ID: 38695144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
    Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
    Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.
    Farrar JE; Schuback HL; Ries RE; Wai D; Hampton OA; Trevino LR; Alonzo TA; Guidry Auvil JM; Davidsen TM; Gesuwan P; Hermida L; Muzny DM; Dewal N; Rustagi N; Lewis LR; Gamis AS; Wheeler DA; Smith MA; Gerhard DS; Meshinchi S
    Cancer Res; 2016 Apr; 76(8):2197-205. PubMed ID: 26941285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.